|
1
|
Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory.
|
Brain
|
2005
|
1.57
|
|
2
|
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.
|
Mov Disord
|
2013
|
1.44
|
|
3
|
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.
|
Mov Disord
|
2012
|
1.15
|
|
4
|
Hallucinations in Parkinson disease.
|
Nat Rev Neurol
|
2009
|
1.13
|
|
5
|
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.
|
Mov Disord
|
2010
|
1.09
|
|
6
|
Neuroimaging of white matter in aging and dementia.
|
Clin Neuropsychol
|
2007
|
0.96
|
|
7
|
Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.
|
Mov Disord
|
2011
|
0.93
|
|
8
|
Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
|
Mov Disord
|
2011
|
0.91
|
|
9
|
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
|
Mov Disord
|
2013
|
0.90
|
|
10
|
Predicting white matter targets for direct neurostimulation therapy.
|
Epilepsy Res
|
2010
|
0.90
|
|
11
|
Analysis of Stereotactic Accuracy in Patients Undergoing Deep Brain Stimulation Using Nexframe and the Leksell Frame.
|
Stereotact Funct Neurosurg
|
2015
|
0.78
|
|
12
|
Commonalities and challenges in the development of clinical trial measures in neurology.
|
Neurotherapeutics
|
2015
|
0.78
|
|
13
|
Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
|
Mov Disord
|
2014
|
0.76
|
|
14
|
Accuracy of Intraoperative Computed Tomography during Deep Brain Stimulation Procedures: Comparison with Postoperative Magnetic Resonance Imaging.
|
Stereotact Funct Neurosurg
|
2017
|
0.75
|
|
15
|
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology.
|
Neurotherapeutics
|
2015
|
0.75
|